Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000667350 | SCV000791784 | likely pathogenic | Cohen syndrome | 2017-05-23 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000667350 | SCV001584717 | pathogenic | Cohen syndrome | 2020-06-25 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in VPS13B are known to be pathogenic (PMID: 15141358, 16648375, 20461111). This variant has not been reported in the literature in individuals with VPS13B-related conditions. ClinVar contains an entry for this variant (Variation ID: 552135). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Leu3414Hisfs*27) in the VPS13B gene. It is expected to result in an absent or disrupted protein product. |
Prevention |
RCV003420178 | SCV004114259 | likely pathogenic | VPS13B-related disorder | 2022-10-21 | criteria provided, single submitter | clinical testing | The VPS13B c.10166_10167delTC variant is predicted to result in a frameshift and premature protein termination (p.Leu3389Hisfs*27). To our knowledge, this variant has not been reported in the literature, but it has been interpreted as likely pathogenic or pathogenic in the ClinVar (https://preview.ncbi.nlm.nih.gov/clinvar/variation/552135/). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Frameshift variants in VPS13B are expected to be pathogenic. This variant is interpreted as likely pathogenic. |